The global sickle cell anemia testing and screening market size is expected to reach USD 829.5 million by 2030, expanding at a CAGR of 12.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Hemoglobin S (HbS) is the causative factor for sickle cell disease and is currently the most prevailing disease or genetic abnormality across the globe, specifically across developing economies.
Sickle cell hemoglobin variants are inclusive of HbS, HbA, and HbC. Different tests have been developed to perform a clear distinction between all the three above-mentioned hemoglobin variants. Development of a deep learning framework designed to perform automated screening of sickle cell anemia in blood smear sample of patients via a smartphone microscope is set to open up new avenues for the market in the near future.
The market is moderately consolidated, wherein the key industry participants are striving to sustain market competition via partnerships, acquisitions, and expanding their business across newborn testing market space. Whereas, emerging companies are exploring potential of point-of-care tests to gain a competitive edge in the market.
A steep increase in the uptake of Hb electrophoresis and HPLC across government-initiated newborn screening programs and assessment studies have resulted in robust market penetration. This has, in turn, caught the attention of companies who are keen on modifying their existing product line, further amplifying consumption of the same.
Request a free sample copy or view report summary: Sickle Cell Anemia Testing & Screening Market Report
By age group, several newborn screening programs have been employed across the globe to effectively manage the burden of this disease. These programs make use of different tests such as isoelectric focusing/ cellulose acetate electrophoresis, high-performance liquid chromatography (HPLC), and solubility tests
Based on technology, POC lateral flow assays are the most preferred testing methodologies in screening programs, forming the conventional means of testing
On the basis of sector type, government laboratories have witnessed maximum employment of sickle cell tests over the years
Government laboratories have actively participated in promoting the adoption of these tests by encouraging population-based sickle cell testing
Rise in the demand for federal and foundation funding to address healthcare disparities treatments and diagnosis of diseases, such as hemoglobinopathies and cystic fibrosis, is expected to drive the attention of the regulatory agencies.
Grand View Research has segmented the global sickle cell anemia testing and screening market report based on technology, age group, sector type, and region:
Sickle Cell Anemia Testing And Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
Hemoglobin Electrophoresis
Isoelectric Focusing
Others
High-Performance Liquid Chromatography (HPLC)
Point-of-Care Tests
Lateral Flow Immunoassay
Paper-Based Rapid Diagnostics
Others
Other Tests
Sickle Cell Anemia Testing And Screening Age Group Outlook (Revenue, USD Million, 2018 - 2030)
Newborn Screening (12 months and below)
Adult Screening (25 to 60 years)
Other Age Groups (1 to 25 & above 60 years)
Sickle Cell Anemia Testing And Screening Sector Type Outlook (Revenue, USD Million, 2018 - 2030)
Government Labs
Private Labs
Corporate Labs
PPP (Public-Private-Partnerships)
Sickle Cell Anemia Testing And Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Sickle Cell Anemia Testing And Screening Market
STRECK, INC
Daktari Diagnostics
BIOMEDOMICS INC.
Laboratory Corporation of America Holdings
Request A Test, Ltd
HALCYON BIOMEDICAL INCORPORATED
Silver Lake Research Corporation
HEMOTYPE
HEMEX HEALTH
Bio-Rad Laboratories, Inc
"The quality of research they have done for us has been excellent..."